110 EAST 59TH STREET, NEW YORK, NY
Earnings Release
2026 Annual General Meeting of Shareholders - Royalty Pharma plc Votes
Material Contracts, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Positive Phase 3 Results for Daraxonrasib in Metastatic PDAC Announced
Annual Report to Security Holders
Reports Q4 and Full Year 2025 Results
FDA Approves MYQORZO for Treatment of Obstructive Hypertrophic Cardiomyopathy
Q2
Q1
FY 2024
Q3
FY 2023
Prospectus Filed Pursuant to Rule 424(b)(2)
Registration Statement for Securities to be Offered to Employees
Prospectus Filed Pursuant to Rule 425
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
Additional Proxy Materials
Definitive Merger Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Free Writing Prospectus
Automatic Shelf Registration Statement